The equipment addresses the problem of ensuring the optimum purity of personal care products, thus avoiding any potential toxins or other hazards from polluting the production process.
This is especially important when the product is in the development stages, but equally important to both the safety and quality during crucial stages of production.
The Ascotec range is used to monitor the quality of the air and compressed gases in the production environment. Most commonly the equipment is used in clean rooms for making a range of personal care products and cosmetics, as well as pharmaceutical products.
The two companies say that the agreement will also mean that they will work together on the development of other products for the detection of contamination.
The supply agreement comes just four months after Biotrace bought up Italian company Microsafe. Part of the £2.5 million deal included the purchase of Microsafe's Ascotec, seen as the principle opportunity for Biotrace to expand its business on a global basis.
Biotrace said that the agreement with Pall would help it to target the US market, and more specifically to achieve the goals of the US FDA Process Analytical Technology (PAT) initiative, which encourages manufacturers to adopt new analytical technologies to better control manufacturing processes and to provide greater assurances of product safety.
Ian Johnson, Biotrace CEO, said: "The combination of Pall's filtration technologies and know how with our technologies and expertise in rapid microbiology will create the next generation of fast testing solutions reducing the 'time to result' and improving production efficiency."